ArticleLeukemia2022
Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07570745 (Low-Dose ATG/PTCy Plus Ivarmacitinib to Prevent Acute Graft-versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation From Parous Female Donors), which is not on this map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low-Dose ATG/PTCy Plus Ivarmacitinib to Prevent Acute Graft-versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation From Parous Female Donors: A Prospective, Single-Arm, Multicenter Trial
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.Blood advances · 2026Trial
- Trial
- A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2023Trial
- Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study.Experimental hematology & oncology · 2026Article
- Selective Janus kinase inhibitors exhibit different effects in murine immune aplastic anemia.HemaSphere · 2026Article
- Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin.Science advances · 2025Article
- BI-5756 Reduces Graft-Versus-Host Disease Through CB1-Mediated Treg Upregulation.Molecules (Basel, Switzerland) · 2025Article
- JAK2 Inhibitors and Emerging Therapies in Graft-Versus-Host Disease: Current Perspectives and Future Directions.Biomedicines · 2025Review
- IRG1/Itaconate inhibits proliferation and promotes apoptosis of CD69Apoptosis : an international journal on programmed cell death · 2024Article
- Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.Molecules (Basel, Switzerland) · 2024Article
- Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.Frontiers in immunology · 2024Review
- Overexpression of S100A9 in donor T cells is associated with reconstitution of gut microbiota and outcome of allogeneic hematopoietic stem cell transplantation.Blood research · 2023Article
- Article
- Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models.Frontiers in immunology · 2023Article
- Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.The Journal of clinical investigation · 2021Article
- Kinase Inhibition as Treatment for Acute and Chronic Graft-Frontiers in immunology · 2021Review
- T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Sena Kim *Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID http://orcid.org/0000-0002-6930-2416
Kidist Ashami *Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Sora LimDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Karl StaserDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Kiran VijDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Srikanth SanthanamInflammatory Bowel Diseases Center and Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Julie RitcheyDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Sarah PetersonDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Feng GaoDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.
Matthew A CiorbaInflammatory Bowel Diseases Center and Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID http://orcid.org/0000-0002-7656-0982
Matthew L CooperDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
John F DiPersioDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID http://orcid.org/0000-0002-0429-3133
Jaebok ChoiDivision of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA. jchoi25@wustl.edu.ORCID http://orcid.org/0000-0002-5590-087X
Washington University in St. Louis · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6MWashington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8MOptimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesR35CA210084 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio · 2017 to 2026
$7.8MTARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCERR01DK109384 · NIDDK · WASHINGTON UNIVERSITY · PI CIORBA, MATTHEW AARON · 2016 to 2020
$1.7MNCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R35 CA210084NIDDK NIH HHS P30 DK052574NIDDK NIH HHS R01 DK109384
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAzetidinesErbB ReceptorsGraft vs Host DiseaseIntestinesJanus Kinase 3MicePurinesPyrazolesSulfonamidesT-Lymphocytes, RegulatoryAzetidinesbaricitinibEGFR protein, mouseErbB ReceptorsJak3 protein, mouseJanus Kinase 3PurinesPyrazolesSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07570745ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.